642. mRNA-1608, an mRNA-Based Therapeutic Genital Herpes Vaccine Candidate: Interim Safety, Immunogenicity and Clinical Endpoint Results from a Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Trial

Open Forum Infect Dis · 2026 · PMC12792503

Europe PMC

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In exploratory analyses, dosing with mRNA-1608 showed a trend for delay in time to first genital herpes recurrence and a decrease in recurrence rate relative to control vaccine.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.